Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System



Status:Active, not recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:40 - Any
Updated:11/10/2018
Start Date:May 2012
End Date:December 2024

Use our guide to learn which trials are right for you!

A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx™ System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer

The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System
when used for single-fraction IORT in early stage breast cancer. Hypothesis: IORT using the
Xoft Axxent eBx System is no worse (non-inferior) than whole breast irradiation (WBI) when
used as stand-alone radiation treatment in breast conserving therapy in women with early
stage breast cancer.

The rationale for IORT as the sole radiation therapy is:

Favorable preliminary results in feasibility, safety and efficacy outcomes: Accelerated
Partial Breast Irradiation (APBI) is an accepted alternative to whole breast irradiation
following breast-conserving surgery for early stage breast cancer. Intra-Operative Radiation
Therapy (IORT) is a form of APBI that allows radiation to be delivered directly to the open
tumor bed following Breast Conservation Surgery (BCS). After 4 years of follow-up, IORT has
shown equivalent disease control rates as whole breast irradiation.

Direct and timely radiation to the tumor bed: Radiation is delivered at to the target tissue
(adjacent to the resection margins at the time of lumpectomy). It avoids treatment delays and
eliminates weeks or months of post-surgical radiation therapy during which residual cancer
cells might proliferate. An in vitro study showed that un-irradiated wound fluid stimulated
the growth of breast cancer cells while irradiated wound fluid did not. Each month of delay
in radiation treatment is associated with a 1% increase in the recurrence rate. Huang, et
al., found a 5.8% recurrence rate in patients who received WBRT within 8 weeks of BCS
compared with a 9.1% recurrence rate in patients who started radiotherapy 9-16 weeks after
BCS.

Increased patient treatment compliance compared to conventional radiation therapy: Suitable
early stage breast cancer patients are able to complete their breast cancer radiotherapy
treatment at the time of BCS, which offers a convenient and potentially life-saving benefit
to patients who might otherwise omit radiation therapy if it required lengthy travel or time
commitments. In addition, healthcare resources, including both personnel and facilities, will
be conserved by eliminating the overhead cost of multiple patient visits, eliminating waiting
time for patients, and consolidating therapy to one visit combined with the surgical
procedure.

Available Technology: The Xoft Axxent controller, x-ray source, and balloon applicator are
cleared by the United States Food and Drug Administration (FDA) to deliver brachytherapy
treatments using high dose rate x-ray radiation. The Xoft Axxent System has been used to
treat breast cancer subjects using a multi-fraction APBI technique on an outpatient basis as
part of two multi-center studies. The Xoft Axxent System enables the Radiation Oncologist to
administer electronic brachytherapy without the use of a radioactive isotope in minimally
shielded rooms. Characteristics of the Xoft System that make it well-suited for IORT include
its portability and low energy photons, allowing for minimal shielding during the radiation
therapy.

This protocol has been developed to further study the use of the Xoft Axxent eBx System in
the delivery of IORT for subjects with early-stage breast cancer. The Xoft Axxent eBx System
will be used according to the United States Food and Drug Administration (FDA) 510(k) cleared
labeling; therefore, the use of the technology in this study is considered on-label and
within the scope of the FDA cleared indication.

Inclusion Criteria:

1. Subject must have provided written Informed Consent

2. Subject must have biopsy-proven invasive ductal carcinoma or ductal carcinoma in situ
of the breast

3. Subject must be female ≥ 40 years of age

4. Subject's tumor(s) must be < 3.0 cm in greatest diameter by pre-operative assessment

5. Subject's tumor(s) must meet AJCC Tumor Classification: Tis, T1 or T2 (< 3 cm), N0, M0

6. Subject presenting with bilateral breast cancer may be enrolled if BOTH cancers meet
all of the inclusion and none of the exclusion criteria

7. Women of child-bearing potential must have a negative pregnancy test within one week
of IORT treatment

8. Women of child-bearing potential must agree to use adequate contraceptive precautions
(defined as oral contraceptives, intrauterine devices, surgical contraceptives or a
combination of condom and spermicide) from the time of negative pregnancy test through
completion of the radiation treatment period

Exclusion Criteria:

1. Subject is pregnant or nursing

2. Subject has significant auto-immune disease

3. Subject has a pacemaker present in the field of radiation or quadrant of the breast
cancer

4. Subject has biopsy-proven multifocal breast cancer

5. Subject has multi-centric breast cancer

6. Subject has known lympho-vascular invasion

7. Subject has invasive lobular cancer

8. Subject has undergone neo-adjuvant chemotherapy or neo-adjuvant endocrine therapy for
current breast cancer

9. Subject has a history of recurrent breast cancer in the ipsilateral breast

10. Subject has had previous radiation exposure of the involved breast

11. Subject has BRCA 1 or 2 mutations. Note: Testing will only be required for Subjects
presenting with bilateral breast cancer; testing is not required for unilateral
cancers

12. Subject has contraindications for radiation

13. Subject considered by the Investigator to be high-risk for breast conservation surgery
and/or intra-operative radiation therapy

14. Subject has participated in any other clinical investigation that is likely to
confound study results or affect study outcome either at the time of IORT or for 3
months prior to IORT.
We found this trial at
27
sites
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Goeffrey Neuner, MD
Phone: 443-849-3123
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
400
Celebration, Florida 34747
Principal Investigator: Olga Ivanov, MD
Phone: 407-303-4594
?
mi
from
Celebration, FL
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Bapsi Chakravarthy, MD
Phone: 615-936-2524
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Bakersfield, California 93306
Principal Investigator: Maureen F. Martin, MD
Phone: 661-326-2174
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Kristen Fernandez, MD
Phone: 443-777-8876
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Casa Grande, Arizona 85122
Principal Investigator: Ajay Bhatnagar, MD
Phone: 520-836-9800
?
mi
from
Casa Grande, AZ
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: William T. Cockerham, MD
Phone: 423-493-1667
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Andrea Madrigrano, MD
Phone: 312-942-3717
?
mi
from
Chicago, IL
Click here to add this to my saved trials
246 Clayton Road
Clayton, Victoria 3168
Principal Investigator: Steven David, MD
Phone: +61 3 9928 8075
?
mi
from
Clayton,
Click here to add this to my saved trials
Coral Gables, Florida 33146
Principal Investigator: Cristina Lopez-Peñalver, MD, FACS
Phone: 786-662-8597
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Denver, Colorado 80220
?
mi
from
Denver, CO
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Veronica Jones, MD
Phone: 626-218-0433
?
mi
from
Duarte, CA
Click here to add this to my saved trials
501 E. Hampden Ave.
Englewood, Colorado 80113
303-788-5000
?
mi
from
Englewood, CO
Click here to add this to my saved trials
Exeter, New Hampshire 03833
Principal Investigator: Gary Proulx, MD
Phone: 603-580-6148
?
mi
from
Exeter, NH
Click here to add this to my saved trials
7950 West Jefferson Boulevard
Fort Wayne, Indiana 48804
Principal Investigator: Rachael A Hayes, MD
Phone: 260-969-7218
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Long Beach, California 90801
Principal Investigator: Nisar Syed, MD
Phone: 562-933-7866
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Los Angeles, California 90095
(310) 825-4321
Principal Investigator: Helena Chang, MD
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oceanside, California 92056
Principal Investigator: Katayoun Toosie, MD
Phone: 760-724-5352
?
mi
from
Oceanside, CA
Click here to add this to my saved trials
1100 N. Lindsay
Oklahoma City, Oklahoma 73104
(405) 271-4000
Principal Investigator: William Dooley, MD
Phone: 405-271-8777
University of Oklahoma The OU Health Sciences Center is composed of seven health-related colleges located...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orange, California 92868
Principal Investigator: Amy Bremner, MD
Phone: 562-981-6101
?
mi
from
Orange, CA
Click here to add this to my saved trials
Phoenix, Arizona 85015
Principal Investigator: Christa Corn, MD
Phone: 602-246-8666
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pleasant Hill, California 94523
Principal Investigator: Sophia Rahman, MD
Phone: 925-825-8878
?
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
475 Seaview Ave
Staten Island, New York 10305
(718) 226-9000
Principal Investigator: Cynara Coomer, MD
Phone: 718-226-8557
Staten Island University Hospital Staten Island University Hospital is a 714-bed, specialized teaching hospital located...
?
mi
from
Staten Island, NY
Click here to add this to my saved trials
Stuart, Florida 34994
Principal Investigator: Craig Wengler, MD
Phone: 772-223-5945
?
mi
from
Stuart, FL
Click here to add this to my saved trials
Tucson, Arizona 85721
(520) 621-2211
Principal Investigator: Victor J. Gonzalez, MD
Phone: 520-626-6800
University of Arizona The University of Arizona is a premier, public research university. Established in...
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Woodbridge, Virginia 22191
?
mi
from
Woodbridge, VA
Click here to add this to my saved trials